Analgecine (AGC), an analgesic for lumbar pain in patients with spinal degenerative diseases, has been shown to inhibit M1-type polarization and promote M2-type polarization by inhibiting TLR4/MyD88/NF-κB signaling pathway, which reduced neuroinflammation during cerebral ischemia (Yang et al., 2021). The gene discussed is MYD88; the disease is brain ischemia.